A5058637025- MicroRNA in disease regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Liver Diseases and Immunity
- Pediatric Hepatobiliary Diseases and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Systemic Lupus Erythematosus Research
- Liver physiology and pathology
- Phagocytosis and Immune Regulation
- Cytomegalovirus and herpesvirus research
Centre de Recherche des Cordeliers
2021-2024
Institut Gustave Roussy
2021-2024
Inserm
2021-2024
Université Paris Cité
2021-2024
Sorbonne Université
2021-2024
Institut Universitaire de France
2024
Université Paris-Saclay
2021-2022
Cholangiocarcinoma (CCA) results from the malignant transformation of cholangiocytes. Primary sclerosing cholangitis (PSC) and primary biliary (PBC) are chronic diseases in which cholangiocytes primarily damaged. Although PSC is an inflammatory condition predisposing to CCA, CCA almost never found autoimmune context PBC. Here, we hypothesized that PBC might favor immunosurveillance. In preclinical murine models challenged with syngeneic (but not PSC) reduced frequency development delayed...
It has been an open conundrum why primary sclerosing cholangitis (PSC) is a major risk factor for developing cholangiocarcinoma (CAA), while biliary (PBC) not. In mouse models of PSC and PBC, it turned out that the latter condition, autoimmune disease affecting bile ducts, reduces transgene-induced cholangiocarcinogenesis, as well progression subcutaneously implanted CCA. This CCA-delaying effect lost upon depletion T lymphocytes involves tumor infiltration by cell clonotypes are also found...